Rockwell Medical (NASDAQ:RMTI) Rating Increased to Hold at Wall Street Zen

Rockwell Medical (NASDAQ:RMTI) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $2.50 price target on shares of Rockwell Medical in a research note on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Rockwell Medical presently has an average rating of “Hold” and a consensus target price of $2.50.

Rockwell Medical Trading Down 7.6%

NASDAQ RMTI opened at $0.87 on Friday. The company has a market capitalization of $34.29 million, a price-to-earnings ratio of -5.80 and a beta of 1.71. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.91 and a quick ratio of 3.50. Rockwell Medical has a 12 month low of $0.78 and a 12 month high of $2.10. The company’s fifty day moving average price is $1.01 and its two-hundred day moving average price is $1.05.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Thursday, March 26th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.05). The company had revenue of $18.35 million during the quarter, compared to the consensus estimate of $18.58 million. Rockwell Medical had a negative return on equity of 16.11% and a negative net margin of 7.67%. As a group, research analysts predict that Rockwell Medical will post 0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after buying an additional 41,668 shares during the period. XTX Topco Ltd boosted its stake in Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after acquiring an additional 46,029 shares during the period. Panagora Asset Management Inc. acquired a new position in Rockwell Medical in the second quarter valued at approximately $41,000. Jane Street Group LLC bought a new position in shares of Rockwell Medical during the fourth quarter valued at approximately $84,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

More Rockwell Medical News

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Achieved adjusted EBITDA profitability for the second straight year, showing improved operating leverage that can support the path to sustainable profitability. Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
• Positive Sentiment: Featured in Zacks screens as a value/momentum candidate — this can attract bargain hunters and momentum traders looking for turnaround stories. Should Value Investors Buy Rockwell Medical (RMTI) Stock?
• Neutral Sentiment: Full Q4 earnings call/transcript provides management commentary and color on drivers of the quarter and the FY26 outlook — useful for investors who want to hear management’s execution plan and assumptions. Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed revenue estimates and reported EPS came in below some consensus figures, signaling slower top‑line momentum; several outlets flagged the revenue decline as the main driver of investor concern. Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Management’s cost‑cutting/right‑sizing plan has raised execution risk and could pressure future growth if not managed carefully — analysts flagged this as a demand/execution risk that may weigh on investor confidence. Rockwell Medical’s Cost Cuts Raise Execution Risk and Threaten Future Growth Prospects
• Negative Sentiment: Company issued a FY26 outlook that some market coverage characterized as cautious after the quarter; investors typically punish missed top‑line results and uncertain guidance more than one‑time positives. Rockwell Medical misses top-line estimates; gives FY26 outlook

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.